+305.3%
APLD vs MRNA
+221.0%
+84.3%
-71.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.8% | -3.4% | -2.3% | -5.5% |
| 7D | +2.7% | -12.1% | +14.8% | +4.0% |
| 30D | -21.4% | -1.3% | -20.1% | -21.2% |
| 3M | -47.8% | +250.9% | -298.8% | -57.3% |
| 6M | -64.9% | +343.0% | -407.9% | -73.9% |
| YTD | -34.9% | +657.4% | -692.3% | -61.1% |
| 1Y | -30.7% | +794.9% | -825.7% | -61.0% |
| 3Y | +305.3% | +218.1% | +87.2% | +157.7% |
| All | +305.3% | +221.0% | +84.3% | +157.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling